Antisense Oligonucleotide Therapeutics Targeting Age-Related Diseases
As people live longer, age-related diseases like Alzheimer’s, heart disease, and arthritis are becoming more common, placing a heavy burden on individuals and healthcare systems. While existing treatments often manage symptoms, they frequently don’t tackle the fundamental biological processes that cause these conditions. A new type of therapy, called antisense oligonucleotides (ASOs), is showing great promise in addressing this gap. ASOs are tiny, synthetic molecules that can specifically interfere with the instructions our genes send to make proteins. Think of our genes as a recipe book, and RNA as the working copy of a recipe. ASOs can intercept or modify these RNA copies, effectively turning down or even switching off the production of harmful proteins or correcting faulty ones. This precise control over gene activity allows scientists to target the very roots of a disease. Researchers are exploring how these therapies can be used for a wide range of age-related conditions, including brain disorders, heart problems, metabolic issues, and bone and muscle diseases. For example, ASOs can help prevent proteins from clumping together, reduce long-term inflammation, correct metabolic imbalances, and lessen tissue scarring – all processes that contribute to aging and disease. While there are still hurdles to overcome, such as ensuring these molecules reach the right tissues in the body and are safe for long-term use, new delivery methods like attaching them to specific targeting molecules or packaging them in tiny fat bubbles (lipid nanoparticles) are making them more effective. This innovative approach has the potential to revolutionize how we treat age-related diseases, moving beyond symptom management to directly addressing their underlying causes.
Source: link to paper